

**Zydus receives final approval from the USFDA for
Clobetasol Propionate Ointment USP**

Ahmedabad, 30 October 2017

Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Ointment USP, 0.05%. The drug is indicated to treat variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
